Javascript must be enabled to continue!
Abstract 1785: Distinct effect of aldehydes in anthracycline cytotoxicity in S. cerevisiae
View through CrossRef
Abstract
Anthracyclines are common chemotherapeutic agents used in many cancers which are refractory to other therapeutic alternatives. In triple negative breast cancer which is commonly observed in African-American women (AA) and tend to be more aggressive, carry worse prognoses and are harder to manage because they lack the molecular targets required for therapies, anthracyclines are some of the few therapeutic alternatives. Although effective, resistance to this agent usually arises and serious side-effects like the development of cardiomyopathy limits their use. To increase our knowledge of the pathways that protect cells from anthracyclines we carried out a genome-wide genetic screening in the eukaryotic model organism S. cerevisiae to identify gene defects that generate cells hypersensitive to doxorubicin. A total of 71 deletion strains displayed varying levels of sensitivity to anthracyclines. Among these, mutants of HOM6 confer significant increased sensitivity to doxorubicin. This effect appears to be due to the accumulation of the threonine intermediate L-aspartate-semialdehyde and can be abolished by the inactivation of a prior step, involving HOM3, which prevents the accumulation of the intermediate. In order to further characterize the synergism of aldehydes and doxorubicin, we have tested the effect of different aldehydes on the cytotoxicity of cells exposed to anthracyclines.
Our data show that treatment with formaldehyde (2 mM) reduced the survival of the wild type strain to 78%. However, in the presence of doxorubicin, formaldehyde reduced the viability of the strain by between 31 to 39-fold (with 10 µM doxorubicin) relative to doxorubicin and formaldehyde alone and by ∼110-fold relative to doxorubicin at 150 µM concentration.
Co-treatment with formaldehyde and doxorubicin of anthracycline-resistant strains siz1 and msh2 also shows increased toxicity. However, the synergistic effect is not as pronounced in these strains compared to the wild type. Among the aldehydes tested, formaldehyde was most effective. Glutaraldehyde and acetaldehyde displayed distinct effect on strains siz1, and ald5. The potential use of a combination of aldehydes and cytotoxic drugs could potentially lead to applications intended to enhance anthracycline-based therapy. This possibility will be discussed, as well as the targeting of aldehydes in relevant human pathways.
Research supported by NIH/NCRR RCMI grant #RR03020 at Florida A&M University.
Citation Format: Jana Sharrae Miles, Tryphon Mazu, Selina Darling-Reed, Hernan Flores-Rozas. Distinct effect of aldehydes in anthracycline cytotoxicity in S. cerevisiae. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1785. doi:10.1158/1538-7445.AM2014-1785
American Association for Cancer Research (AACR)
Title: Abstract 1785: Distinct effect of aldehydes in anthracycline cytotoxicity in S. cerevisiae
Description:
Abstract
Anthracyclines are common chemotherapeutic agents used in many cancers which are refractory to other therapeutic alternatives.
In triple negative breast cancer which is commonly observed in African-American women (AA) and tend to be more aggressive, carry worse prognoses and are harder to manage because they lack the molecular targets required for therapies, anthracyclines are some of the few therapeutic alternatives.
Although effective, resistance to this agent usually arises and serious side-effects like the development of cardiomyopathy limits their use.
To increase our knowledge of the pathways that protect cells from anthracyclines we carried out a genome-wide genetic screening in the eukaryotic model organism S.
cerevisiae to identify gene defects that generate cells hypersensitive to doxorubicin.
A total of 71 deletion strains displayed varying levels of sensitivity to anthracyclines.
Among these, mutants of HOM6 confer significant increased sensitivity to doxorubicin.
This effect appears to be due to the accumulation of the threonine intermediate L-aspartate-semialdehyde and can be abolished by the inactivation of a prior step, involving HOM3, which prevents the accumulation of the intermediate.
In order to further characterize the synergism of aldehydes and doxorubicin, we have tested the effect of different aldehydes on the cytotoxicity of cells exposed to anthracyclines.
Our data show that treatment with formaldehyde (2 mM) reduced the survival of the wild type strain to 78%.
However, in the presence of doxorubicin, formaldehyde reduced the viability of the strain by between 31 to 39-fold (with 10 µM doxorubicin) relative to doxorubicin and formaldehyde alone and by ∼110-fold relative to doxorubicin at 150 µM concentration.
Co-treatment with formaldehyde and doxorubicin of anthracycline-resistant strains siz1 and msh2 also shows increased toxicity.
However, the synergistic effect is not as pronounced in these strains compared to the wild type.
Among the aldehydes tested, formaldehyde was most effective.
Glutaraldehyde and acetaldehyde displayed distinct effect on strains siz1, and ald5.
The potential use of a combination of aldehydes and cytotoxic drugs could potentially lead to applications intended to enhance anthracycline-based therapy.
This possibility will be discussed, as well as the targeting of aldehydes in relevant human pathways.
Research supported by NIH/NCRR RCMI grant #RR03020 at Florida A&M University.
Citation Format: Jana Sharrae Miles, Tryphon Mazu, Selina Darling-Reed, Hernan Flores-Rozas.
Distinct effect of aldehydes in anthracycline cytotoxicity in S.
cerevisiae.
[abstract].
In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1785.
doi:10.
1158/1538-7445.
AM2014-1785.
Related Results
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract
[Background]In adjuvant settings of HER2 positive cancer, trastuzumab has been shown to be effective in combination with anthracycline- based chemotherapy f...
Abstract PS12-04: HDACi combined with anthracycline elicits interactions between MHC-II+ triple-negative breast cancer and CD69+CD4+Trm orchestrating synergistic immunotherapy
Abstract PS12-04: HDACi combined with anthracycline elicits interactions between MHC-II+ triple-negative breast cancer and CD69+CD4+Trm orchestrating synergistic immunotherapy
Abstract
Background: Early TNBC (eTNBC) lacks biomarkers for predicting the benefits of immune checkpoint blockade (ICB). Therefore, identifying indicators for the h...
Risk Factors for Anthracycline-Induced Cardiotoxicity
Risk Factors for Anthracycline-Induced Cardiotoxicity
Background: Several cardiovascular risk factors have been suggested to be associated with anthracycline-induced cardiotoxicity, but their quantitative effects have not reached a co...
Assessment of growth and fermentation of some yeasts on soybean residue hydrolysate
Assessment of growth and fermentation of some yeasts on soybean residue hydrolysate
This study explored the growth and fermentation capabilities of four distinct yeast strains, including Saccharomyces cerevisiae var. boulardii CNCM I-745, S. cerevisiae 7012, S. ce...
Production of transglutaminase in glutathione-producing recombinant Saccharomyces cerevisiae
Production of transglutaminase in glutathione-producing recombinant Saccharomyces cerevisiae
AbstractTransglutaminase (TG) catalyzes the formation of cross-links between proteins. TG from Streptoverticillium mobaraense (SmTG) is used widely in food, cosmetic, biomaterial a...
Increasing Survivors of Anthracycline-related Cardiomyopathy with Breast Cancer in Trastuzumab Era: Thirty-one-Year Trends in a Japanese Community
Increasing Survivors of Anthracycline-related Cardiomyopathy with Breast Cancer in Trastuzumab Era: Thirty-one-Year Trends in a Japanese Community
Abstract
BACKGROUND
Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardio...
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Abstract
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-induced cardiotoxicity effectively. In this study, we aimed to (1)...
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Abstract
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-induced cardiotoxicity effectively. In this study, we aimed to (1)...


